BioInsights - Industrializing immuno-oncology product manufacture and supply chain - spotlight

CELL & GENE THERAPY INSIGHTS

June 2022

Industrializing immuno-oncology product manufacture and supply chain

Download PDF

Expert Insight

A new era of in vivo gene therapy: the applicability of a differentiated HSV-1 based vector platform for redosable medicines

A new era of in vivo gene therapy: the applicability of a differentiated HSV-1 based vector platform for redosable medicines

T Parry, S Krishnan, D Prosdocimo

Innovator Insight

Scaling non-viral cell therapy approaches for solid tumor treatments

Scaling non-viral cell therapy approaches for solid tumor treatments

E Zynda, N Andronikou, K Jacoby

Commentary

Why we need a revolution for personalized cell therapies

Why we need a revolution for personalized cell therapies

S Steiner, B Gilgen, E Pernot et al.

Interview

Blazing a trail for commercial TCR T cell therapy

Blazing a trail for commercial TCR T cell therapy

Helen Tayton-Martin

Preparing next-gen cellular immunotherapies for commercialization

Preparing next-gen cellular immunotherapies for commercialization

Peter Olagunju

FastFacts

Key considerations for cytokine supplier selection for cell therapies

Key considerations for cytokine supplier selection for cell therapies

Timothy Manning

Driving CAR-T from early-stage development to clinical filing and lot release

Driving CAR-T from early-stage development to clinical filing and lot release

U Herbrand, J Schueler, S Vermond

Webinars

Thinking translational: Things to consider in CAR T cell research workflows

Thinking translational: Things to consider in CAR T cell research workflows

Saskia Rösch, PhD

Forward engineering cell therapy production capabilities to save patient lives

Forward engineering cell therapy production capabilities to save patient lives

John Lee, PhD